Q2 2025 Management View Brian Lian, President and CEO, reported that "the Viking team continued to focus on execution of our core clinical strategy," emphasizing advancement of both oral and ...

At the CCOI-Stanford Summit, Goldberg calls for collaborative trial models that could redefine efficiency and standardization ...

Loss per share was $(0.58), falling short of analyst expectations by $(0.13), or 29.1% (GAAP, Q2 2025). - Research and development expenses rose to $60.2 million in Q2 2025, up from $23.8 million in ...

AbCellera's AI-driven drug discovery model hasn't translated into meaningful growth. Click here to read an analysis of ABCL ...

Research and development collaboration program to include additional models of lymphoma and leukemia to further validate ...

Medpace has historically maintained a conservative balance sheet. At year-end 2024, cash and cash equivalents totaled $669 million. Medpace generated nearly $191 million in cash flow from operating ...

The Trump administration’s proposed cuts to medical research and health agencies will curtail the development of promising ...

ARPA-H, part of HHS, has earmarked up to $142 million for 10 research projects building the tools, data, and infrastructure needed to tackle treatment resistance.

"We believe Mr. Kelly's well-documented ability to prioritize clinical program development, execute successful financings, and attract the attention of large industry peers will help maximize ...

The French pharma is taking the lead on clinical development and potential commercialization for both programs, with Antares eligible to receive milestone payments and royalties.

“Following positive results from our first clinical study in 2024, which evaluated the safety and immunogenicity of our Launch-iT technology platform, starting the clinical development with our first ...